The pineal hormone melatonin (Mel), in addition to having a well-established role as a regulator of circadian rhythms, modulates nonneural compartments by acting on specific plasma membrane receptors (MT1/MT2) present in many different cell types. Mel plays immunomodulatory roles and is an oncostatic and antiproliferative agent; this led to the widespread belief that Mel may induce or potentiate apoptosis on tumor cells, even though no clear indications have been presented so far. Here we report that Mel is not apoptogenic on U937 human monocytic cells, which are known to possess MT1 receptors at the times (up to 48 h) and doses (up to 1 mM) tested. Mel does not even potentiate apoptosis, but instead, significantly reduces apoptosis induced by both cell-damaging agents (intrinsic pathway) and physiological means (extrinsic pathway). The doses required for the antiapoptotic effect (>or=100 microM) are apparently not compatible with receptor stimulation (receptor affinity<1 nM). However, receptor involvement cannot be ruled out, because we discovered that the actual Mel concentration active on cells was lower than the nominal one because of sequestration by fetal calf serum (FCS). Accordingly, in FCS-free conditions, Mel doses required for a significant antiapoptotic effect are much lower.

Radogna, F., Paternoster, L., Albertini, M., Accorsi, A., Cerella, C., D'Alessio, M., et al. (2006). Melatonin as an apoptosis antagonist. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1090, 226-233 [10.1196/annals.1378.025].

Melatonin as an apoptosis antagonist

RADOGNA, FLAVIA;DE NICOLA, MILENA;MAGRINI, ANDREA;BERGAMASCHI, ANTONIO;GHIBELLI, LINA
2006-12-01

Abstract

The pineal hormone melatonin (Mel), in addition to having a well-established role as a regulator of circadian rhythms, modulates nonneural compartments by acting on specific plasma membrane receptors (MT1/MT2) present in many different cell types. Mel plays immunomodulatory roles and is an oncostatic and antiproliferative agent; this led to the widespread belief that Mel may induce or potentiate apoptosis on tumor cells, even though no clear indications have been presented so far. Here we report that Mel is not apoptogenic on U937 human monocytic cells, which are known to possess MT1 receptors at the times (up to 48 h) and doses (up to 1 mM) tested. Mel does not even potentiate apoptosis, but instead, significantly reduces apoptosis induced by both cell-damaging agents (intrinsic pathway) and physiological means (extrinsic pathway). The doses required for the antiapoptotic effect (>or=100 microM) are apparently not compatible with receptor stimulation (receptor affinity<1 nM). However, receptor involvement cannot be ruled out, because we discovered that the actual Mel concentration active on cells was lower than the nominal one because of sequestration by fetal calf serum (FCS). Accordingly, in FCS-free conditions, Mel doses required for a significant antiapoptotic effect are much lower.
dic-2006
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/44 - MEDICINA DEL LAVORO
English
Con Impact Factor ISI
Blood Proteins; Apoptosis; Humans; Culture Media; Melatonin; U937 Cells
Radogna, F., Paternoster, L., Albertini, M., Accorsi, A., Cerella, C., D'Alessio, M., et al. (2006). Melatonin as an apoptosis antagonist. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1090, 226-233 [10.1196/annals.1378.025].
Radogna, F; Paternoster, L; Albertini, M; Accorsi, A; Cerella, C; D'Alessio, M; DE NICOLA, M; Nuccitelli, S; Magrini, A; Bergamaschi, A; Ghibelli, L...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/66569
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact